Response Genetics Inc. company was founded in 1999 and is headquartered in Los Angeles, California. Response Genetics, Inc., a life sciences company, engages in the research, development, marketing, and sale of clinical diagnostics and pharmacogenomic tests for use in the treatment of cancer in the United States, Europe, and Japan. It offers ResponseDX: Lung test suite, which comprises KRAS Mutation and EGFR Amplification tests. The KRAS Mutation test identifies tumors that have low probability of response to EGFR-directed therapy. The EGFR Amplification test assesses the probability of benefit from EGFR-directed therapy. The company also offers ResponseDX: Colon test suite that includes ERCC1, KRAS Mutation, and TS tests. The ERCC1 test is a test for the probability of response to platin-based therapies and the analysis of RRM1 tests for the probability of response to gemcitabine-based therapies. The TS test measures the probability of response to 5-fluorouracil -based chemotherapy. In addition, Response Genetics, Inc. is developing tests of other types of cancer that identify genetic profiles of tumors that recur after surgery. The company has collaboration agreements with Shanghai BioChip Company, Ltd. to provide pharmacogenomic testing services in China using the company's RGI-1 extraction technology; and Hitachi Chemical Co., Ltd. to use its techniques to extract genetic information from formalin-fixed paraffin-embedded tissue samples. It offers its services in the areas of oncology for oncologists, hospitals, and physician offices through the sales force.

Insmed Incorporated Company was founded in 1999 and is headquartered in Richmond, Virginia. Insmed Incorporated, a development stage company, engages in the development of recombinant protein drug. The company's primary product includes IPLEX, a complex of recombinant human IGF-1 and its binding protein IGFBP-3 for use in the treatment of several serious medical conditions, as well as conducting a phase III enabling clinical trial for investigating IPLEX as a treatment for myotonic muscular dystrophy. Insmed also engages in various oncology programs, including INSM-18, an orally available small molecule tyrosine kinase inhibitor that has demonstrated selective inhibition of IGF-1 and human epidermal growth factor receptor; and rhIGFBP-3, which is in early clinical development stage for the treatment of breast, prostate, liver, ovarian, and colon cancers. The company also provides Expanded Access Program in Italy to offer IPLEX to physicians for use in their patients with amyotrophic lateral sclerosis. It has a license to Pharmacia AB's portfolio of regulatory filings pertaining to rhIGF; and an agreement with NAPO Pharmaceuticals that gives NAPO the right to develop, manufacture, and commercialize masoprocal products for various indications relating to diabetes, cardiac disease, vascular disease, metabolic disease, and syndrome X.

Cedarburg Hauser, formerly Cedarburg Pharmaceuticals, makes drugs, components of drugs, and ingredients for drugs. The contract manufacturer does everything from project management to manufacturing to validating study results. It produces custom chemicals, natural and synthetic active pharmaceutical ingredients, dietary supplements, and cosmetics. And, because Cedarburg Hauser also holds Drug Enforcement Agency permits, it makes controlled substances including pain killers and other narcotics. Other services include process development and a whole host of analytical services including quality control and stability studies.

CPEX Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development, licensing, and commercialization of pharmaceutical products utilizing its validated drug delivery technology. Its drug delivery technology, CPE-215 technology, enhances permeation and absorption of pharmaceutical molecules across biological membranes such as the skin, nasal mucosa and eye. The company's principal product Testim, a gel for testosterone replacement therapy is licensed to Auxilium Pharmaceuticals, Inc. that markets the product in the United States, Europe, and other countries. It also holds U.S. and international patents, and other proprietary rights to technologies that facilitate the absorption of drugs. In addition, CPEX Pharmaceuticals, Inc. is developing an intranasal insulin product candidate, Nasulin, which is in Phase II clinical trials. The company was incorporated in 2007 and is headquartered in Exeter, New Hampshire.

Phenomix hopes to create a pharmaceutical phenomenon by investigating and discovering new treatments for immune system ailments and metabolic diseases. The drug development company's lead product candidate dutogliptin is an oral-dose treatment aiming to stabilize glucose levels in patients with Type 2 diabetes. Other pipeline candidates target infectious and autoimmune diseases, including hepatitis C and certain types of cancer. The biotechnology firm's drug candidates focus on inhibiting complex proteins (enzymes) that promote disease within the body. The company is owned by a number of private investors.

Amarin Corporation plc (Amarin) is a late-stage biopharmaceutical company with a focus on cardiovascular disease. Amarin has a range of clinical and preclinical stage compounds to treat central nervous system (CNS) disorders, including Huntington’s disease, myasthenia gravis and Parkinson’s disease. Its cardiovascular programs and non-core CNS programs include AMR101, EN101, Sublingual Apomorphine and AMR 103. The Company's subsidiaries include Amarin Neuroscience Limited, Amarin Pharmaceuticals Ireland Limited, Amarin Pharma Inc, Amarin Finance Limited and Ester Neurosciences Limited.

Clinimetrics Research Associates, Inc. company is a contract research organization (CRO) that provides clinical research services, consulting, project management, data management, and electronic data capture services through most stages of clinical trials. Its services aim to control costs for customers including global biotechnology, pharmaceutical, and medical device companies. It specializes in biotech development, as well as in therapeutic areas such as oncology and cardiology research. Clinimetrics has locations throughout North America. The company is a subsidiary of institutional pharmacy operator Omnicare.

Genentech, Inc. (Genentech) is a biotechnology company that discovers, develops, manufactures and commercializes pharmaceutical products to treat patients with unmet medical needs. It commercializes multiple biotechnology products and also receives royalties from companies that are licensed to market products based on the Company’s technology. Genentech commercializes various products in the United States, including Avastin, Rituxan, Herceptin, Lucentis, Xolair, Tarceva, Nutropin, Activase, TNKase, Cathflo Activase, Pulmozyme and Raptiva. The Company’s licensed products include Trastuzumab, Rituximab, Bevacizumab, Dornase alfa, recombinant, Alteplase and Tenecteplase, Somatropin, Daclizumab, Ranibizumab, Etanercept, Adalimumab and Infliximab. In March 2009, Roche Holding Ltd. completed the acquisition of Genentech.

Nexgen Pharma (formerly Anabolic Laboratories) is a contract manufacturer of nutritional supplements and prescription and over-the-counter pharmaceuticals. Its dietary supplements line includes vitamins, minerals, herbs, and other nutraceuticals. Nexgen Pharma's pharmaceutical contract manufacturing operations can make a variety of formulations, including immediate-release and controlled-release tablets, chewable tablets, effervescent tablets, and powder-filled capsules. The company also helps clients with formulation development, product testing, regulatory filing assistance, and other product development services. Nexgen has facilities in Arizona, California, and Colorado.

Guerbet Group is one of Europe's leading makers of contrast agents used in medical imaging. Most of the company's products, such as Xenetix, Hexabrix, and Dotarem, are substances that are injected into the body to make internal organs visible during X-ray and magnetic resonance imaging (MRI) examinations. Subsidiary Simafex manufactures specialty chemicals for use in pharmaceuticals. Guerbet has operations in some 15 countries and is targeting growth in the US. Marcel Guerbet, grandfather of chairman Michel Guerbet, developed the first iodinated contrast agent around the turn of the century; his descendants control the company.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.